What is Femasys's market cap?

Femasys (FEMY) has a market capitalization of $440.9K and trades on NASDAQ.

Who are Femasys's competitors?

Femasys's key competitors include CooperSurgical, Progyny, Inc. Common Stock, Utah Medical Products Inc, and others. These companies compete in similar markets and product categories.

Who does Femasys partner with?

Femasys's notable partners include Boston IVF, HRC Fertility, CNY Fertility, and others.

Where is Femasys headquartered?

Femasys is headquartered in United States of America and employs approximately 34 people. It has been publicly traded since 2021.

Femasys

FEMY

Femasys Inc. is a biomedical innovator focused on developing and commercializing minimally invasive, in-office therapeutic and diagnostic solutions for women's health.

Market cap

$440.85K-98.4%

Table of contents

Earnings

Q1 2026 report

May 8, 2026

Revenue$424.9KMiss by $342.1K EPS$0.00Beat by $0.07

Read the full report

Next report

Aug 12, 2026 (In 2 weeks)

Revenue estimate$730.7K

EPS estimate-$1.27

Competitors

By market cap

The Cooper Companies, Inc.$13.7B-5.8%

Progyny$2.5B+24.4%

Pediatrix Medical Group$2.1B+97.2%

UFP Technologies$1.9B+2.0%

Utah Medical Products$220.0M+18.4%

Biomerica$5.0M-47.7%

INVO Fertility, Inc.$1.7M-13.4%

Femasys$440.9K-98.4%

By revenue growth

UFP Technologies+11.2%

Progyny+6.6%

The Cooper Companies, Inc.+6.1%

Pediatrix Medical Group-2.3%

Utah Medical Products-7.0%

By net margin

Utah Medical Products29.04%-3.3pp

UFP Technologies11.27%-0.3pp

Pediatrix Medical Group9.02%+14.5pp

The Cooper Companies, Inc.5.57%-4.8pp

Progyny5.23%+0.9pp

Profile

Femasys Inc. is a biomedical innovator focused on developing and commercializing minimally invasive, in-office therapeutic and diagnostic solutions for women's health. The company's core value proposition centers on providing accessible, non-surgical alternatives to traditional procedures in reproductive health, specifically addressing infertility and permanent birth control.

Competitive position

A pioneer in non-surgical permanent birth control and intratubal insemination with an extensive global patent portfolio and in-house manufacturing capabilities.

GeographiesUnited States, European Union, Canada, United Kingdom, Israel, Japan

Customer segmentsHealthcare Providers, Specialized Medical Practices, Fertility Clinics

Business modelMedical Device Manufacturing, Direct Sales, International Distribution

SuppliersRaw material suppliers, Contract component manufacturers, Third-party sterilizers

CustomersGynecology practices, Reproductive endocrinology clinics, Infertility center conglomerates, International medical distributors

CountryUnited States of America

Listed2021

Employees34.0

CEOKathy Lee-Sepsick

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitefemasys.com

FilingsSEC EDGAR

Questions, answered.

What is Femasys's market cap?: Femasys (FEMY) has a market capitalization of $440.9K and trades on NASDAQ.
Who are Femasys's competitors?: Femasys's key competitors include CooperSurgical, Progyny, Inc. Common Stock, Utah Medical Products Inc, and others. These companies compete in similar markets and product categories.
Who does Femasys partner with?: Femasys's notable partners include Boston IVF, HRC Fertility, CNY Fertility, and others.
Where is Femasys headquartered?: Femasys is headquartered in United States of America and employs approximately 34 people. It has been publicly traded since 2021.